BYSI - BeyondSpring Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

12.0M

Cash

37.27M

Avg Qtr Burn

-6.866M

Short % of Float

8.32%

Insider Ownership

29.70%

Institutional Own.

15.31%

Qtr Updated

12/31/22

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Plinabulin (Tubulin selective immunomodulating microtubule-binding agent) Details Non-small cell lung carcinoma, Lung cancer	NDA FDA meeting	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Plinabulin (Tubulin selective immunomodulating microtubule-binding agent) Details Chemotherapy-induced neutropenia, Cancer	NDA FDA meeting	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.